A Phase 1 Study to Evaluate EGFRvIII -Targeted Chimeric Antigen Receptor (CAR) T Cells for Adult Patients With Leptomeningeal Glioblastoma
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Anti-EGFRvIII CAR T-cell therapy-Chembrain LTD/University of Oulu (Primary)
- Indications Glioblastoma; Meningeal carcinomatosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARTREMENDOUS
- Sponsors Chembrain
- 11 Oct 2021 New trial record